Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.52 |
| ▸ | CA2 | P00918 | 7/20 | 0.52 |
| ▸ | CA12 | O43570 | 6/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12856657 | 0.92 | CA1 (0.55) | CA1CA2CA12CA14CA7 | |
| SCHEMBL28412908 | 0.83 | GRIA1 (0.37) | CA1CA2CA12CA14CA7 | |
| SCHEMBL3208052 | 0.82 | CA2 (0.38) | CA1CA2CA12CA14CA7 | |
| SCHEMBL27695076 | 0.81 | GRIA1 (0.41) | CA1CA2CA12PPARACA9 | |
| SCHEMBL1145734 | 0.79 | CA1 (0.50) | CA1CA2CA12CA14CA7 | |
| SCHEMBL1145060 | 0.79 | CA2 (0.56) | CA1CA2CA12PPARACA9 | |
| SCHEMBL4070914 | 0.79 | POLB (0.44) | CA1CA2CA12CA14CA7 | |
| SCHEMBL5147794 | 0.78 | — | — | |
| SCHEMBL4628337 | 0.77 | RELA (0.44) | CA1CA2CA12CA9GRIA1 | |
| SCHEMBL9952157 | 0.77 | GRIA1 (0.43) | CA1CA2CA12CA14CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293256-B2 | Sulfamide derivatives and cosmetic use thereof | L'OREAL (FR) | 2012-10-23 | — | — | US | disclosed |
| US-8293256-B2 | Sulfamide derivatives and cosmetic use thereof | L'OREAL (FR) | 2012-10-23 | — | — | US | disclosed |
| US-20110044918-A1 | Novel sulfamide derivatives and cosmetic use thereof | L'OREAL (FR) | 2011-02-24 | — | — | US | disclosed |
| US-20110044918-A1 | Novel sulfamide derivatives and cosmetic use thereof | L'OREAL (FR) | 2011-02-24 | — | — | US | disclosed |
| US-7887824-B2 | such as N,N'-bis(2-hydroxyethyl)sulfamide; improved elasticity on stratum corneum | L'OREAL (FR) | 2011-02-15 | — | — | US | disclosed |
| US-7887824-B2 | such as N,N'-bis(2-hydroxyethyl)sulfamide; improved elasticity on stratum corneum | L'OREAL (FR) | 2011-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110044918-A1 | Novel sulfamide derivatives and cosmetic use thereof | STS, TST, TPST2 | CA1 4083/4885CA2 1701/4885CA12 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.